Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

Authors not listed

Weill Medical College of Cornell University · 2021

Abstract

The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2021). Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease. <em>Weill Medical College of Cornell University</em>. https://clinicaltrials.gov/study/NCT04984330
Vancouver
Anonymous. Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease. Weill Medical College of Cornell University. 2021.
BibTeX
@misc{anon2021Seline, title = {Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease}, author = {Anonymous}, journal = {Weill Medical College of Cornell University}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings